The whole market is going down currently. MYGN will fall back sharply.>>
Weak market opening provides great opportunity to pick up more stock in MYGN as amateurs sell. This stock should not be traded. It should be positioned in high risk accounts on weakness with a 3 year holding objective in mind.
Be careful with MYGN's ambition to start a PIII without knowing PII result. I think it is most likely a last pump the company is playing, before it announces the failure of the PII trial. Otherwise, they should have landed a partnership with a big Pharm Co. on PIII. To me it seems no big Pharm wants to jump in. Very risky!!!
You will see a big secondary offer to dilute the share soon following this pump. Run as fast as you can now.
Ah, shucks. One of the only molecules with statin-like revenue potential, in advanced human testing and with a clean phase I and strong preclinical rationale, and MYGN has it all to themselves??? Shucks, shucks, shucks.